NW Bio to Present at the Cancer Immunotherapy Summit
BETHESDA, Md., Feb. 29, 2012 /PRNewswire/ — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO, Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm ET on Wednesday, February 29, 2012, in Boston, Massachusetts at the Metro Meeting Center at 101 Federal Street.
Dr. Maida’s presentation, entitled “Developing Immune Therapies with Multiple Complementary Product Lines,” will address the various components of developing a dendritic cell vaccine based on a patient’s own tumor tissue. Using NW Bio’s DCVax®-L vaccine platform technology for solid tumor cancers as an example, Dr. Maida will discuss the identification of clinically relevant tumor antigens (biomarkers), clinical trial design, assessment of immune response and clinical efficacy, and tumor evasion tactics. In addition, Dr. Maida will address manufacturing with scale-up strategies, and commercial development of active immune therapies.
The three day conference on this rapidly expanding field of future cancer treatment potential is directed at featuring “industry innovators blazing a trail towards successful and sustained commercialization.” Dr. Maida’s longstanding experience in the field and NW Bio’s progress to date will be presented in support of the Conference’s key theme of “Re-engineering the Immune System for Effective Management of Cancer.”
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe.
The Company has a broad platform technology for dendritic cell-based vaccines. The Company’s lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme (“GBM”), the most aggressive and lethal brain cancer. In the earlier Phase I/II clinical trials for GBM brain cancer, patients who received DCVax® showed a median survival of 3 years compared with median survival of 14.6 months for patients who received standard of care (surgery, radiation and chemotherapy). Patients who received DCVax® also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care. DCVax® was well-tolerated, with no toxic side effects.
The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. For further information about clinical sites and about the Company, please visit the Company’s web site at www.nwbio.com.
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.